Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA/CMS Parallel Review: Firms Lack Incentive To Participate, Lawyers Say

Executive Summary

As drug industry advisors scrutinize FDA’s and CMS’ recent proposal to institute voluntary parallel reviews of new medical products, some are seeing little reason for manufacturers to subject their products to parallel review.
Advertisement

Related Content

Comparative Evidence Needs Earlier Consideration In Drug Development Process – Novartis Exec
IPAB Will Make CMS More Relevant In Parallel Reviews With FDA, Former Official Gottlieb Predicts
IPAB Will Make CMS More Relevant In Parallel Reviews With FDA, Former Official Gottlieb Predicts
FDA/CMS Parallel Review Not Needed For Biopharma Products – PhRMA And BIO
FDA/CMS Parallel Review Not Needed For Biopharma Products – PhRMA And BIO
Parallel Review: End Of Phase II Could Be Best Time For CMS Involvement
Provenge Coverage With Data Collection Suggested By MEDCAC Members
Provenge Coverage With Data Collection Suggested By MEDCAC Members
Parallel Review Could Deter NCD, Medicare Exec Says; Provenge A Case In Point?
CMS/FDA Parallel Review: Agencies Weighing Process For Planning Trials That Satisfy Both

Topics

Advertisement
UsernamePublicRestriction

Register

PS052929

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel